Aprea Therapeutics (APRE) Current Assets (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Current Assets of $47.2 million for Q1 2026, up 138.2% year-over-year from $19.8 million in Q1 2025, and up 203.61% quarter-over-quarter from $15.6 million in Q4 2025.
Aprea Therapeutics (APRE) Current Assets (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Current Assets for 9 consecutive years, with $47.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 138.2% year-over-year to $47.2 million; the TTM figure through Mar 2026 stood at $47.2 million (up 138.2% YoY), while the FY2025 annual figure was $15.6 million, down 34.0% from the prior year.
- Current Assets rose to $47.2 million in Q1 2026 per APRE's latest filing, from $15.6 million in the prior quarter.
- Across five years, Current Assets topped out at $50.0 million in Q1 2022 and bottomed at $13.9 million in Q3 2025.
- Historically, Current Assets has averaged $28.8 million across 5 years, with a median of $28.6 million in 2023.
- Annual changes were most pronounced in 2025 — Current Assets tumbled 47.35% — and 2026, when it jumped 138.2%.
- Aprea Therapeutics' Current Assets stood at $30.2 million in 2022, then fell by 25.31% to $22.5 million in 2023, then increased by 4.68% to $23.6 million in 2024, then sank by 34.0% to $15.6 million in 2025, then surged by 203.61% to $47.2 million in 2026.
- Business Quant data shows APRE's Current Assets at $47.2 million in Q1 2026, $15.6 million in Q4 2025, and $13.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Aprea Therapeutics | 34.28 Mn | 34.28 Mn | - | 41.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.91 Mn |
| Mar 31, 2026 | 47.25 Mn |
| Dec 31, 2025 | 15.56 Mn |
| Sep 30, 2025 | 13.94 Mn |
| Jun 30, 2025 | 16.93 Mn |
| Mar 31, 2025 | 19.83 Mn |
| Dec 31, 2024 | 23.58 Mn |
| Sep 30, 2024 | 26.48 Mn |
| Jun 30, 2024 | 29.56 Mn |
| Mar 31, 2024 | 33.07 Mn |
| Dec 31, 2023 | 22.52 Mn |
| Sep 30, 2023 | 25.64 Mn |
| Jun 30, 2023 | 28.64 Mn |
| Mar 31, 2023 | 32.02 Mn |
| Dec 31, 2022 | 30.15 Mn |
| Sep 30, 2022 | 33.47 Mn |
| Jun 30, 2022 | 40.46 Mn |
| Mar 31, 2022 | 50.04 Mn |
| Dec 31, 2021 | 56.58 Mn |
| Sep 30, 2021 | 62.18 Mn |